HIV Medicine最新文献

筛选
英文 中文
Immune outcomes with dolutegravir-based dual therapy versus bictegravir-based triple therapy: A multinomial propensity score analysis. 以双替格雷韦为基础的双重治疗与以双替格雷韦为基础的三联治疗的免疫结果:多项倾向评分分析
IF 3.2 3区 医学
HIV Medicine Pub Date : 2026-11-12 DOI: 10.1111/hiv.70365
Jesús Troya, Guillermo Pousada, Ignacio de Los Santos, Rafael Micán, Carlos Galera, José Sanz, Alberto Díaz de Santiago, José Antonio Iribarren, Estela Moreno, Miguel Ángel Morán, Julia Gómez, Pepa Galindo, Cristina Martín, Carlos Dueñas, Luis Buzón-Martín
{"title":"Immune outcomes with dolutegravir-based dual therapy versus bictegravir-based triple therapy: A multinomial propensity score analysis.","authors":"Jesús Troya, Guillermo Pousada, Ignacio de Los Santos, Rafael Micán, Carlos Galera, José Sanz, Alberto Díaz de Santiago, José Antonio Iribarren, Estela Moreno, Miguel Ángel Morán, Julia Gómez, Pepa Galindo, Cristina Martín, Carlos Dueñas, Luis Buzón-Martín","doi":"10.1111/hiv.70365","DOIUrl":"https://doi.org/10.1111/hiv.70365","url":null,"abstract":"<p><strong>Objectives: </strong>To compare immune outcomes after switching to dolutegravir/lamivudine (DTG/3TC), dolutegravir/rilpivirine (DTG/RPV) and bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF).</p><p><strong>Methods: </strong>Three Spanish cohorts of adults with baseline HIV-RNA <50 copies/mL were harmonized. Multinomial propensity scores were used for 13 baseline variables. Stabilized inverse probability weights were winsorized at the 1st/99th percentiles. The primary outcome was baseline-adjusted CD4+ T-cell count at week 48. Bootstrap confidence intervals and Holm's correction were used.</p><p><strong>Results: </strong>Of 3057 eligible participants, 1794 had complete covariates and 1438 had week-48 CD4+ T-cell counts. B/F/TAF versus DTG/3TC and DTG/RPV differences were -7.4 (95% CI -45.1 to 30.4) and +5.6 (-24.6 to 35.7) cells/μL (both Holm p = 1.000). Additional baseline CD4+ T-cell percentage adjustment changed the former to -39.8 (-78.5 to -1.2). CD4+ T-cell percentage differences were + 1.66 and + 1.44 percentage points (both Holm p ≤ 0.002). Original secondary CD8+ T-cell count differences were - 92.9 and - 96.5 cells/μL (both Holm p = 0.007); the ratio difference versus DTG/3TC was +0.165 (Holm p = 0.013).</p><p><strong>Conclusions: </strong>In these three Spanish cohorts, the primary propensity score-adjusted analysis did not detect a difference between regimens in the week-48 CD4+ T-cell count. Original secondary analyses associated B/F/TAF with lower CD8+ T-cell counts than both dual regimens and a higher CD4+/CD8+ T-cell ratio than that of DTG/3TC. The CD8+ T-cell count and ratio contrasts versus DTG/3TC attenuated after additional baseline percentage adjustment. These associations were sensitive to baseline immune adjustment, and their clinical relevance warrants further investigation.</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149405251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beyond borders: Making HIV prevention and care work for people on the move. 超越国界:为流动人群提供艾滋病预防和护理服务。
IF 3.2 3区 医学
HIV Medicine Pub Date : 2026-11-10 DOI: 10.1111/hiv.70360
Fiona Burns, Miłosz Parczewski, Esteban Martinez
{"title":"Beyond borders: Making HIV prevention and care work for people on the move.","authors":"Fiona Burns, Miłosz Parczewski, Esteban Martinez","doi":"10.1111/hiv.70360","DOIUrl":"https://doi.org/10.1111/hiv.70360","url":null,"abstract":"","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149386366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HIV/AIDS burden in South Asia, 1990-2023: Temporal trends, sex differences and attributable risk factors from the Global Burden of Disease study 2023. 1990-2023年南亚艾滋病毒/艾滋病负担:《2023年全球疾病负担研究》的时间趋势、性别差异和归因风险因素
IF 3.2 3区 医学
HIV Medicine Pub Date : 2026-11-09 DOI: 10.1111/hiv.70362
Zaryab Bacha, Syed Tawassul Hassan, Faryal Ali, Mahrukh Mahrukh, Mahveen Iqbal, Iftikhar Ahmad, Nimra Azhar, Hafiz Hamza Ahmad Choudhry, Rimsha Faisal, Saeeda Zahid, Bilal Wazir Khan, Wajiha Babar, Haris Hamsakutty
{"title":"HIV/AIDS burden in South Asia, 1990-2023: Temporal trends, sex differences and attributable risk factors from the Global Burden of Disease study 2023.","authors":"Zaryab Bacha, Syed Tawassul Hassan, Faryal Ali, Mahrukh Mahrukh, Mahveen Iqbal, Iftikhar Ahmad, Nimra Azhar, Hafiz Hamza Ahmad Choudhry, Rimsha Faisal, Saeeda Zahid, Bilal Wazir Khan, Wajiha Babar, Haris Hamsakutty","doi":"10.1111/hiv.70362","DOIUrl":"https://doi.org/10.1111/hiv.70362","url":null,"abstract":"<p><strong>Objectives: </strong>To describe levels and trends of the HIV/AIDS burden in the Global Burden of Disease (GBD) South Asia region and its five countries, 1990-2023, including sex differences and risk-attributable burden.</p><p><strong>Methods: </strong>We analysed GBD 2023 estimates of HIV/AIDS incidence, prevalence, deaths and disability-adjusted life years (DALYs) for Bangladesh, Bhutan, India, Nepal and Pakistan. Joinpoint regression was applied to all 72 location-sex-measure series of age-standardized rates (ASRs) to estimate average annual percentage changes (AAPCs) and the annual percentage change (APC) of the most recent segment. Risk-attributable burden was obtained from the GBD comparative risk assessment.</p><p><strong>Results: </strong>In 2023, South Asia had 99 748 new HIV infections, 58 627 HIV/AIDS deaths and 3 056 866 DALYs; India accounted for 80.9% of deaths. Regional ASRs peaked in 1997 (incidence) and 2006 (deaths) and have since declined (AAPC 2010-2023: incidence -4.61% (95% CI -4.83 to -4.40); deaths -7.80% (95% CI -8.06 to -7.55)). Pakistan was the only country in which incidence, prevalence and mortality were still increasing (incidence APC 2005-2023: 5.54% (95% CI 3.87 to 7.24)) and had the highest incidence ASR (14.55 per 100 000). Male rates exceeded female rates for incidence and prevalence, whereas regional mortality rates converged (male-to-female ratio 1.03). Unsafe sex was associated with 69.3% of regional HIV/AIDS deaths and drug use with 39.6% of deaths in Pakistan.</p><p><strong>Conclusions: </strong>The regional HIV/AIDS burden in South Asia has declined since the mid-2000s, but this conceals a continuing increase in Pakistan and slower progress in Bangladesh. Country-specific prevention, testing and harm-reduction responses, supported by stronger surveillance, are needed.</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149378695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Estimating the potential need for HIV pre-exposure prophylaxis in Italy: A national modelling study. 估计意大利艾滋病毒暴露前预防的潜在需求:一项国家模型研究。
IF 3.2 3区 医学
HIV Medicine Pub Date : 2026-11-08 DOI: 10.1111/hiv.70364
Davide Moschese, Fabrizio Tediosi, Chiara Fusetti, Alice Baratelli, Sara Laura Ferrari, Maria Letizia Oreni, Andrea Gori
{"title":"Estimating the potential need for HIV pre-exposure prophylaxis in Italy: A national modelling study.","authors":"Davide Moschese, Fabrizio Tediosi, Chiara Fusetti, Alice Baratelli, Sara Laura Ferrari, Maria Letizia Oreni, Andrea Gori","doi":"10.1111/hiv.70364","DOIUrl":"https://doi.org/10.1111/hiv.70364","url":null,"abstract":"<p><strong>Objectives: </strong>Despite the expanding implementation of HIV pre-exposure prophylaxis (PrEP) across Europe, substantial gaps in access and uptake remain. We aimed to estimate the size and distribution of the population potentially eligible for PrEP in Italy using available demographic, epidemiological and behavioural data.</p><p><strong>Methods: </strong>A deterministic modelling framework was developed to estimate the population potentially eligible for PrEP in Italy. The model integrated national demographic data with epidemiological and behavioural indicators associated with increased HIV acquisition risk. Estimates were generated for key population groups, including men who have sex with men (MSM), cisgender heterosexual men and women and transgender and non-binary individuals. Female sex workers were assessed separately because of potential overlap with other risk categories.</p><p><strong>Results: </strong>The model estimated that approximately 205 000 individuals in Italy may be eligible for PrEP (range: 170000-240 000). MSM accounted for the majority of the potentially eligible population, with an estimated 162 000 individuals (≈79%). Additional populations included 29 000 cisgender heterosexual men (≈14%), 9500 cisgender heterosexual women (≈5%) and 4600 transgender and non-binary individuals (≈2%). A further 13 900 female sex workers were estimated to engage in substantial HIV risk behaviours; however, they were excluded from the overall total because of possible overlap with other population groups.</p><p><strong>Conclusions: </strong>Our findings suggest that a substantial number of individuals at risk of HIV acquisition in Italy may be eligible for PrEP, with MSM representing the largest group but with important contributions from other populations traditionally underrepresented in PrEP programmes. Although some estimates relied on dated survey data and proxy assumptions, the results highlight the need for strengthened national PrEP surveillance and monitoring systems, improved characterization of underserved populations and targeted strategies to reduce gaps in PrEP access and uptake.</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149378694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Structural determinants of outcomes related to the prevention of vertical HIV transmission: A cross-country ecological analysis. 与预防艾滋病毒垂直传播有关的结果的结构性决定因素:一项跨国生态分析。
IF 3.2 3区 医学
HIV Medicine Pub Date : 2026-11-08 DOI: 10.1111/hiv.70361
Zeynep Oğul, Eda Yakıt Ak, Özden Tandoğan
{"title":"Structural determinants of outcomes related to the prevention of vertical HIV transmission: A cross-country ecological analysis.","authors":"Zeynep Oğul, Eda Yakıt Ak, Özden Tandoğan","doi":"10.1111/hiv.70361","DOIUrl":"https://doi.org/10.1111/hiv.70361","url":null,"abstract":"<p><strong>Objective: </strong>This study examined the longitudinal associations of epidemiological, health system and structural factors with paediatric HIV infections and antiretroviral therapy (ART) need among pregnant women in 30 high-burden countries.</p><p><strong>Methods: </strong>This longitudinal cross-country ecological study used secondary data from international databases covering 2000-2024. A total of 30 countries were included based on HIV burden and data availability. Data were sourced from UNAIDS (indicators related to the prevention of vertical HIV transmission), WHO/UNICEF (maternal health services) and the World Bank (socioeconomic variables). Missing data were handled using linear interpolation and last observation carried forward (LOCF) to create a balanced panel. Datasets were harmonized by country and year. Linear mixed-effects models were used to account for repeated observations within countries, with year included as a fixed effect and country specified as a random-intercept grouping factor.</p><p><strong>Results: </strong>Adult HIV prevalence showed substantial variability across countries and years. In the linear mixed-effects model, higher adult HIV prevalence was significantly associated with higher levels of log paediatric HIV infections (B = 0.129, p < 0.001) and log ART need among pregnant women (B = 0.086, p < 0.001). Higher ANC coverage was significantly associated with lower levels of both log paediatric HIV infections (B = -0.008, p < 0.001) and log ART need (B = -0.006, p < 0.001). GDP per capita was not significantly associated with log paediatric HIV infections (B = -0.00003, p = 0.127), whereas it was positively associated with log ART need (B = 0.000033, p = 0.004). Paediatric HIV infections decreased significantly over time (B = -0.059, p < 0.001), while year was not significantly associated with ART need (B = -0.00088, p = 0.626). Strong country-level clustering was observed for both outcomes (ICC = 0.921 and 0.975, respectively).</p><p><strong>Conclusions: </strong>Higher adult HIV prevalence was associated with higher paediatric HIV infections and ART need, whereas higher ANC coverage was associated with lower levels of both outcomes. GDP showed outcome-specific associations, and substantial between-country variability was observed. These findings highlight the importance of epidemic burden and maternal health service coverage in understanding outcomes related to the prevention of vertical HIV transmission.</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149378707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pregnancy and neonatal outcomes after prenatal exposure to dolutegravir: Data from a European cohort collaboration. 产前暴露于多替格拉韦后的妊娠和新生儿结局:来自欧洲队列合作的数据
IF 3.2 3区 医学
HIV Medicine Pub Date : 2026-11-08 DOI: 10.1111/hiv.70359
Rebecca Sconza, Georgina Fernandes, Virginia Rasi, Heather Bailey, Karoline Aebi-Popp, Luminita Ene, Marco Floridia, Anna Gamell, Marta Illán Ramos, Helen Peters, Anna Samarina, Giorgia Dalla Valle, Gabija Morkunaite, Carlo Giaquinto, Leigh Ragone, Annemiek de Ruiter, Vani Vannappagari, Claire Thorne
{"title":"Pregnancy and neonatal outcomes after prenatal exposure to dolutegravir: Data from a European cohort collaboration.","authors":"Rebecca Sconza, Georgina Fernandes, Virginia Rasi, Heather Bailey, Karoline Aebi-Popp, Luminita Ene, Marco Floridia, Anna Gamell, Marta Illán Ramos, Helen Peters, Anna Samarina, Giorgia Dalla Valle, Gabija Morkunaite, Carlo Giaquinto, Leigh Ragone, Annemiek de Ruiter, Vani Vannappagari, Claire Thorne","doi":"10.1111/hiv.70359","DOIUrl":"https://doi.org/10.1111/hiv.70359","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to assess 'real-world' pregnancy and neonatal outcomes following prenatal dolutegravir (DTG) use in a European setting.</p><p><strong>Methods: </strong>We conducted a pooled analysis of individual-patient data from seven observational studies. Pregnancies with DTG exposure any time from the periconception period (≤6 completed gestational weeks) were included. Congenital anomalies were assessed using criteria defined by the World Health Organization International Classification of Diseases: Tenth Revision (ICD-10) and the European Network of population-based registries for the epidemiological surveillance of congenital anomalies (EUROCAT).</p><p><strong>Results: </strong>Of 827 pregnancies, there were 764 live births, 37 miscarriages, 21 terminations and five stillbirths. No congenital anomalies were identified in the five stillborn infants. One termination was due to an identified congenital anomaly. Excluding four infants with chromosomal abnormalities, 34 live-born infants had 37 anomalies. There were no central nervous system abnormalities. Live birth prevalence of congenital anomalies was 4.4% (95% CI 3.0, 6.1) according to ICD-10; for infants with earliest DTG exposure in the periconception period, later in the first trimester and in the second/third trimester, prevalence was 4.7% (22/470), 2.6% (1/38) and 4.1% (11/265), respectively. Prevalence according to EUROCAT classification was 3.5% (95% CI 2.3, 5.0) overall. In live-born singletons with earliest exposure at periconception/first trimester and second/third trimesters, 13.6% (66/485) and 13.7% (32/255) were preterm and 9.7% (46/474) and 6.5% (16/246) were small for gestational age, respectively.</p><p><strong>Conclusions: </strong>Our data on prenatal DTG use do not demonstrate increased risk of congenital anomalies compared to expected rates. Ongoing monitoring is needed to exclude association with rare anomalies.</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149378696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Applying the CONSENSUS-LAI virological failure definition in real-world practice: Evidence from the multicentre LAHIV cohort. 在现实世界实践中应用CONSENSUS-LAI病毒学失败定义:来自多中心LAHIV队列的证据
IF 3.2 3区 医学
HIV Medicine Pub Date : 2026-11-06 DOI: 10.1111/hiv.70363
F Lagi, B Rossetti, M Fabbiani, D Nigi, G Sarteschi, A Pampaloni, S Costarelli, C Bianco, S Modica, L Pisano, D Messeri, A Bartoloni
{"title":"Applying the CONSENSUS-LAI virological failure definition in real-world practice: Evidence from the multicentre LAHIV cohort.","authors":"F Lagi, B Rossetti, M Fabbiani, D Nigi, G Sarteschi, A Pampaloni, S Costarelli, C Bianco, S Modica, L Pisano, D Messeri, A Bartoloni","doi":"10.1111/hiv.70363","DOIUrl":"https://doi.org/10.1111/hiv.70363","url":null,"abstract":"<p><strong>Objectives: </strong>Definitions of virological failure (VF) for long-acting cabotegravir plus rilpivirine (CAB+RPV) remain inconsistent across real-world cohorts. The CONSENSUS-LAI Delphi process (September 2025) set a shared plasma threshold of ≥200 copies/mL. We evaluated its impact on VF classification and whether its publication influenced prescriber behaviour.</p><p><strong>Methods: </strong>Retrospective analysis of virologically suppressed adults initiating CAB+RPV across 11 centres in Tuscany, Italy. Switches attributed to VF by the treating physician were reclassified as meeting CONSENSUS-LAI plasma criteria or as sub-threshold. Rates were calculated per 100 person-years (PY); switches before and after September 2025 were compared with Fisher's exact test.</p><p><strong>Results: </strong>Among 297 participants (418 PY), 11 switches were attributed to VF (2.63/100 PY, 95% CI 1.31-4.71). Six (54.5%) met CONSENSUS-LAI plasma criteria (1.44/100 PY, 95% CI 0.53-3.12), five with a single value >1000 copies/mL, one with confirmed values ≥200 copies/mL; 4 were sub-threshold and one was cerebrospinal fluid viral escape with undetectable plasma HIV-1 RNA. Emergent resistance occurred in three cases, all CONSENSUS-LAI-defined failures. No resistance was detected in the two sub-threshold cases tested; all four sub-threshold VF re-suppressed, although two of four were switched to a protease inhibitor-based regimen. Sub-threshold switches were 1/6 before and 3/5 after CONSENSUS-LAI publication (p = 0.24).</p><p><strong>Conclusions: </strong>The CONSENSUS-LAI definition nearly halves the VF rate, aligning it with cohorts using a ≥200 copies/mL threshold. Emergent resistance was confined to CONSENSUS-LAI-defined failures, whereas sub-threshold viraemia, without detected resistance, still drove most post-consensus switches, highlighting the challenges of translating consensus recommendations into routine practice.</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of the coronavirus disease 2019 (COVID-19) pandemic and stringency index on the dispensation of human immunodeficiency virus post-exposure prophylaxis in Brazil: A retrospective study. 2019冠状病毒病(COVID-19)大流行和严格指数对巴西人类免疫缺陷病毒暴露后预防分配的影响:一项回顾性研究
IF 3.2 3区 医学
HIV Medicine Pub Date : 2026-11-05 DOI: 10.1111/hiv.70343
Matheus Negri Boschiero, Nathália Mariana Santos Sansone, Fernando Augusto Lima Marson
{"title":"Impact of the coronavirus disease 2019 (COVID-19) pandemic and stringency index on the dispensation of human immunodeficiency virus post-exposure prophylaxis in Brazil: A retrospective study.","authors":"Matheus Negri Boschiero, Nathália Mariana Santos Sansone, Fernando Augusto Lima Marson","doi":"10.1111/hiv.70343","DOIUrl":"https://doi.org/10.1111/hiv.70343","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;The coronavirus disease 2019 (COVID-19) pandemic substantially affected healthcare systems worldwide and may have compromised access to human immunodeficiency virus (HIV) prevention strategies, including post-exposure prophylaxis (HIV-PEP). However, evidence regarding temporal changes in HIV-PEP dispensation and their association with restrictive governmental measures in Brazil remains limited. Therefore, this study aimed to evaluate the dynamics of HIV-PEP dispensation in Brazil before, during and after the COVID-19 pandemic and to investigate its temporal association with the COVID-19 Stringency Index.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This retrospective epidemiological study used secondary data from the Brazilian Ministry of Health HIV-PEP Monitoring Panel between 2018 and 2024. The study period was categorized into pre-pandemic (until February 2020), pandemic (March 2020 to May 2023) and post-Public Health Emergency of International Concern (post-PHEIC; from June 2023 onward) periods. An interrupted time-series analysis (ITSA) using negative binomial regression was performed to evaluate temporal changes in HIV-PEP dispensation, including immediate-level changes and changes in trends associated with the pandemic and post-PHEIC periods. Additional generalized linear mixed-effects models were used to evaluate factors associated with the volume of recorded HIV-PEP dispensation events, with a random intercept for Brazilian state. Data on the COVID-19 Stringency Index were obtained from the Oxford COVID-19 Government Response Tracker. Exploratory analyses using negative binomial regression and Spearman correlation were performed to evaluate the temporal association between the Stringency Index and HIV-PEP dispensation.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;From 2018 to 2024, 863 201 HIV-PEP dispensation events were recorded in Brazil, most frequently in the Southeast region (54%). Consensual sexual exposure accounted for most dispensation events (69%), followed by accidents involving biological material (26%). Before the pandemic, HIV-PEP dispensation showed an increasing temporal trend (rate ratio [RR] = 1.019; 95% confidence interval [95% CI]: 1.015, 1.024). At the onset of the COVID-19 pandemic, an immediate reduction in the number of recorded HIV-PEP dispensation events was observed (RR = 0.657; 95% CI: 0.604, 0.714). The volume of dispensations subsequently resumed an increasing trajectory during both the pandemic (RR = 1.016; 95% CI: 1.014, 1.018) and post-PHEIC periods (RR = 1.013; 95% CI: 1.006, 1.020), although the observed trajectory remained below the pre-pandemic trajectory. In the adjusted mixed-effects model, the expected number of recorded HIV-PEP dispensation events was lower during both the pandemic (RR = 0.74; 95% CI: 0.71, 0.76) and post-PHEIC periods (RR = 0.75; 95% CI: 0.71, 0.79). In the primary temporal model, the Stringency Index was inversely associated with HIV-PEP dispensation (RR = 0.968; 95% CI","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149333750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beyond HIV prevention: Reframing PrEP clinics as hubs for viral hepatitis prevention and elimination. 超越艾滋病毒预防:将PrEP诊所重塑为病毒性肝炎预防和消除中心。
IF 3.2 3区 医学
HIV Medicine Pub Date : 2026-11-03 DOI: 10.1111/hiv.70345
Francesco De Maria, Francesco Branda, Paolo Fusco, Giancarlo Ceccarelli, Fabio Scarpa, Massimo Ciccozzi, Alessandro Russo
{"title":"Beyond HIV prevention: Reframing PrEP clinics as hubs for viral hepatitis prevention and elimination.","authors":"Francesco De Maria, Francesco Branda, Paolo Fusco, Giancarlo Ceccarelli, Fabio Scarpa, Massimo Ciccozzi, Alessandro Russo","doi":"10.1111/hiv.70345","DOIUrl":"https://doi.org/10.1111/hiv.70345","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objectives: &lt;/strong&gt;The expansion of HIV pre-exposure prophylaxis (PrEP) has created a growing network of prevention services that regularly engage people who may also be exposed or susceptible to viral hepatitis. PrEP care is inherently longitudinal, involving repeated clinical assessment, laboratory testing, counselling and vaccination review. These features make PrEP clinics uniquely positioned to contribute to viral hepatitis prevention and elimination. In this narrative review, we synthesize evidence on the integration of viral hepatitis prevention, screening, diagnosis and care within PrEP services, and propose a practical framework, the PrEP-viral hepatitis elimination cascade, for translating the principle of integrated HIV, viral hepatitis and sexually transmitted infection services into routine clinical practice.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A focused literature search was conducted between 1 May and 8 August 2026 across PubMed/MEDLINE, Embase, Scopus and the WHO Global Index Medicus, using documented search strings supplemented by hand-searching of reference lists. We prioritized studies conducted among PrEP users or within PrEP programmes, together with relevant international guidelines and policy documents. Records were screened in two stages against predefined eligibility criteria, and the findings were mapped to the steps of the cascade. Evidence was sought on HAV and HBV vaccination coverage, HBV seroprevalence and susceptibility, the relationship between tenofovir-based PrEP and HBV prevention, HCV epidemiology among PrEP users, simplified diagnostic strategies and integrated service delivery models. Given the heterogeneity of study designs and outcomes, the literature was synthesized narratively rather than through formal meta-analysis. Interventions and indicators for each cascade step were then summarized in an evidence-linked implementation and monitoring table.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The evidence consistently demonstrates that vaccination gaps for HAV and HBV persist among PrEP users, with suboptimal initiation and completion rates across settings; that HBV susceptibility remains common among individuals entering PrEP care; and that tenofovir-based PrEP, while offering incidental HBV protection, should not substitute for vaccination. HCV epidemiology among PrEP users is heterogeneous, supporting risk-adapted testing strategies, while simplified diagnostic pathways and self-testing approaches have shown promise for HCV. The PrEP-viral hepatitis elimination cascade proposed here offers a structured, implementable framework connecting vaccination, case finding, linkage to care and longitudinal reassessment within the existing PrEP pathway. The cascade is presented as a detailed figure and as an implementation and monitoring table linking each step to supporting evidence, candidate interventions and measurable indicators, without assigning responsibilities to specific providers. Implementation challenges ","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149320725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Wellbeing of trans and gender-diverse people with HIV in the United Kingdom: Results from Positive Voices 2022 英国跨性别和性别多样化的艾滋病毒感染者的福祉:积极之声2022年的结果。
IF 3.2 3区 医学
HIV Medicine Pub Date : 2026-11-02 Epub Date: 2026-08-27 DOI: 10.1111/hiv.70286
H. Kitt, C. Kelly, A. Aghaizu, M. Ross, F. C. Lampe, C. J. Smith, V. Martin, C. Humphreys, A. Brown, A. Sparrowhawk, M. Kall, J. Sewell, E. Wainwright, V. Delpech, G. Davis, A. Farah, A. Fasanya, A. J. Rodger, T. Đuretić, PV2022 Study Group
{"title":"Wellbeing of trans and gender-diverse people with HIV in the United Kingdom: Results from Positive Voices 2022","authors":"H. Kitt,&nbsp;C. Kelly,&nbsp;A. Aghaizu,&nbsp;M. Ross,&nbsp;F. C. Lampe,&nbsp;C. J. Smith,&nbsp;V. Martin,&nbsp;C. Humphreys,&nbsp;A. Brown,&nbsp;A. Sparrowhawk,&nbsp;M. Kall,&nbsp;J. Sewell,&nbsp;E. Wainwright,&nbsp;V. Delpech,&nbsp;G. Davis,&nbsp;A. Farah,&nbsp;A. Fasanya,&nbsp;A. J. Rodger,&nbsp;T. Đuretić,&nbsp;PV2022 Study Group","doi":"10.1111/hiv.70286","DOIUrl":"10.1111/hiv.70286","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This national cross-sectional observational study aimed to assess mental health, quality of life, supportive network, experiences of HIV-related stigma in healthcare and unmet service need among trans and gender-diverse people with HIV, compared to cisgender people with HIV.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Positive Voices 2022 is a questionnaire survey of people accessing HIV care in England, Scotland and Wales carried out in 2022 and 2023 that included measures of depression and anxiety symptoms and suicidal ideation (PHQ-9 and GAD-7), health-related quality of life (EQ-5D-5L), supportive network (modified Duke FSSQ), experiences of HIV-related stigma in healthcare and service needs. Logistic and ordinal logistic regression assessed the association of gender identity with these measures unadjusted and adjusted for age group and ethnicity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Overall, 67 trans or gender-diverse and 4551 cisgender people with HIV participated. Compared to cisgender participants, trans and gender-diverse participants were younger, more likely to be Asian and less likely to be black. They were less likely to be in employment, homeowners and financially secure. Trans and gender-diverse participants had a higher prevalence of depression symptoms (35.5% [22/62] vs. 20.5% [865/4219], adjusted odds ratio [aOR] [95% confidence interval, CI] = 1.96 [1.15, 3.34]; <i>p</i> = 0.014) and suicidal ideation (37.1% [23/62] vs. 14.6% [616/4219]; aOR = 3.09 [1.85, 5.17]; <i>p</i> &lt; 0.001) compared to cisgender participants. They also had poorer health-related quality of life for three domains (anxiety and depression, usual activities and self-care) and lower levels of supportive network in unadjusted and adjusted analyses. A higher proportion of trans and gender-diverse participants than cisgender participants had unmet needs for health services, including mental health services (49.2% [31/63] vs. 30.2% [1310/4343]; aOR = 2.02 [1.22–3.35]; <i>p</i> = 0.007), lifestyle services, and welfare and social services.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Trans and gender-diverse people with HIV have poorer mental health and wellbeing than cisgender people with HIV, and a higher prevalence of unmet service needs, highlighting the need for access to culturally competent mental health and other health and welfare services.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"27 11","pages":"1763-1777"},"PeriodicalIF":3.2,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hiv.70286","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148840233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书